ATLANTA, GA – – (Globe Newswire – September 3, 2026) – – A shareholder class action lawsuit has been filed against Unicycive Therapeutics, Inc. (“Unicycive”) (NASDAQ: UNCY). The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts, including allegations that: (1) Unicycive had not inspected its third-party manufacturing vendor’s facility or otherwise audited the facility’s compliance with current good manufacturing practices; (2) as a result, Unicycive lacked a reasonable basis to believe that the vendor had resolved the FDA’s cited deficiencies; (3) there was an undisclosed risk that the FDA would require additional information about the vendor’s facility’s manufacturing practices; (4) as a result of the foregoing, the regulatory approval of oxylanthanum carbonate was reasonably likely to be delayed; and (5) as a result of the foregoing, Defendants’ positive statements about Unicycive’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

 If you purchased Unicycive shares between December 29, 2025 and June 29, 2026, and experienced a loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/unicycive-therapeutics/ for more information.

The deadline to ask the court to be appointed lead plaintiff in the case is November 2, 2026.